Cargando…
Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
BACKGROUND: The adverse events (AEs) of rituximab (RTX) for neuromyelitis optica spectrum disorder (NMOSD) are incompletely understood. AIM: To collate information on the reported the AEs of RTX in NMOSD and assess the quality of evidence. METHODS: PubMed, EMBASE, Web of Science, Cochrane Library, W...
Autores principales: | Wang, Hao, Zhou, Juanping, Li, Yi, Wei, Lili, Xu, Xintong, Zhang, Jianping, Yang, Kehu, Wei, Shihui, Zhang, Wenfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689613/ https://www.ncbi.nlm.nih.gov/pubmed/34950240 http://dx.doi.org/10.1177/17562864211056710 |
Ejemplares similares
-
Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials
por: Xu, Xintong, et al.
Publicado: (2022) -
Corrigendum to: Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
Publicado: (2022) -
Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience
por: Jade, Jui Dilip, et al.
Publicado: (2017) -
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
por: Nosadini, Margherita, et al.
Publicado: (2016) -
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
por: Marcinnò, Andrea, et al.
Publicado: (2018)